>new indications Nobody's gonna drop huge cash on a Alz clinical big enough to get a FDA approval for a ubiquitous molecule with 0 market exclusivity. EPA is done. All that's left is whatever Amarin can scape out of the EU market for the next 7 years and that's not looking good.